(2R,3S)-N-[(2S)-3-cyclohexyl-1-(methylamino)-1-oxopropan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2R,3S)-N-[(2S)-3-cyclohexyl-1-(methylamino)-1-oxopropan-2-yl]-N',3-dihydroxy-2-(2-methylpropyl)butanediamide
• 化学式: C₁₈H₃₃N₃O₅
• 分子量: 371.5
• InChiKey: USIZLNWLYBSOFO-ILXRZTDVSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  9
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  128
• 氢给体数：
  5
• 氢受体数：
  5

文献信息

• UTILIZATION OF TACE INHIBITORS FOR THE TREATMENT OF ACNE
  申请人：AUBERT JÉRÔME

  公开号：US20100168089A1

  公开（公告）日：2010-07-01

  An in vitro method of screening for candidate compounds for the preventive or curative treatment of acne entails determination of the ability of a compound to inhibit the expression or the activity of TACE, and also to the administration of inhibitors of the expression or of the activity of this enzyme, in the treatment of acne.

  一种体外筛选预防或治疗痤疮候选化合物的方法，需要确定化合物抑制TACE（酶）表达或活性的能力，并且使用这种酶表达或活性的抑制剂进行痤疮治疗。
• Method of using a COX-2 inhibitor and a TACE inhibitors as a combination therapy
  申请人：Pharmacia Corporation

  公开号：US20040122011A1

  公开（公告）日：2004-06-24

  The present invention provides compositions and methods to treat, prevent or inhibit a neoplasia, a neoplasia-related disorder, pain, inflammation, an inflammatory-related disorder, a vaso-occlusive event or a vaso-occlusive-related disorder in a mammal using a combination of a COX-2 inhibitor and a TACE inhibitor.

  本发明提供了一种使用COX-2抑制剂和TACE抑制剂的组合物和方法，以治疗、预防或抑制哺乳动物中的肿瘤、肿瘤相关疾病、疼痛、炎症、炎症相关疾病、血管闭塞性事件或血管闭塞性相关疾病。
• US7413727B2
  申请人：——

  公开号：US7413727B2

  公开（公告）日：2008-08-19
• [EN] PHARMACOLOGICAL CHAPERONES FOR THE TREATMENT OF ALZHEIMER'S DISEASE<br/>[FR] CHAPERONS PHARMACOLOGIQUES POUR LE TRAITEMENT DE LA MALADIE D’ALZHEIMER
  申请人：AMICUS THERAPEUTICS INC

  公开号：WO2011011181A1

  公开（公告）日：2011-01-27

  The invention relates to methods of enhancing normal α-secretase expression, and to enhancing expression of an α-secretase having a mutation which affects protein folding and/or processing of the α-secretase. The invention provides a method of treating an individual having a condition in which increased expression or activity of an α-secretase in the central nervous system would be beneficial, by administering an effective amount of a pharmacologic chaperone for the α-secretase. The invention provides α-secretase inhibitors which have been identified as specific pharmacologic chaperones which enhance expression or enzymatic activity of α-secretase in the central nervous system.